Hormonal
Dual-PPARα/γ agonists (glitazars) like muraglitazar, tesaglitazar, and aleglitazar have largely failed in clinical development for type 2 diabetes and cardiovascular disease due to severe safety concerns, including heart failure, renal dysfunction, and increased mortality.
Do not seek out dual-PPAR agonists like muraglitazar or aleglitazar. These drugs were developed for diabetes and heart health but were withdrawn from the market because they caused serious side effects like heart failure and kidney problems. Stick to established treatments with proven safety profiles.
High risk-to-benefit ratio led to the cessation of further development on muraglitazar, tesaglitazar, aleglitazar, and MK0767. ... In a Phase III clinical trial (AleCardio), treatment with aleglitazar—a dual PPARα/γ agonist, failed to modify cardiovascular risk among T2DM patients but, instead, was associated with severe adverse effects, like heart failure, gastrointestinal hemorrhages, and renal dysfunction [78].
Why this rating
Based on terminated Phase III trials and post-hoc analyses, indicating strong evidence of failure.
Source
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Hong Sheng Cheng et al. · International Journal of Molecular Sciences · 2019
DOI 10.3390/ijms20205055
More from this paper
- PPARγ agonist pioglitazone significantly reduces the risk of major cardiovascular events (stroke and myocardial infarction) in patients with type 2 diabetes and high cardiovascular risk, including those with prediabetes.Good
- PPARα agonists (fibrates) significantly reduce cardiovascular events and myocardial infarction in subjects without existing cardiovascular disease, making them effective for primary prevention.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →